Retatrutide vs Ozempic now has a direct trial result: Lilly reported greater blood-sugar reductions and weight loss with retatrutide in adults with type 2 diabetes. That is evidence about a possible future treatment. Retatrutide is still being tested, and the full trial report is still to come.
Retatrutide vs Ozempic: what Lilly reported
As of October 29, 2026, the day this article was written, Lilly has announced TRANSCEND-T2D-2 results dated October 28. This late-stage, phase 3 trial compared retatrutide with Ozempic, the semaglutide medicine, over 80 weeks.
Lilly reports 1,298 participants whose diabetes was inadequately controlled with metformin, a diabetes medicine, with or without an SGLT2 inhibitor, another type of diabetes pill. Treatment was assigned by chance. The trial was open-label, meaning participants and investigators knew which medicine each person received.
The registered primary outcome, or main measurement, is “Change from Baseline in Hemoglobin A1c (HbA1c) (%)” at week 80. A1C reflects average blood sugar over roughly three months. The trial's main question was whether retatrutide 12 mg lowered it at least as well as Ozempic 2 mg. Lilly reports that 12 mg also lowered it more than Ozempic under the trial's pre-planned statistical controls; for 9 mg, the larger A1C drop is reported only as nominally significant, a weaker statistical standard.
| At 80 weeks | Retatrutide 9 mg | Retatrutide 12 mg | Ozempic 2 mg |
|---|---|---|---|
| A1C change from an average 8.3% | −2.2 percentage points | −2.2 percentage points | −1.8 percentage points |
| Average body-weight change | −19.5% | −20.9% | −9.4% |
These are Lilly's efficacy estimand figures: an analysis estimating results had everyone stayed on their assigned treatment for all 80 weeks, with dose pauses or changes allowed, without starting another blood-sugar medicine for more than 14 days. Lilly's release reports only this analysis, not one that counts people who stopped. They describe group averages under that assumption, not a forecast for one person.
The earlier placebo comparison belongs to TRIUMPH-2's diabetes results. Here, the comparison was with an active medicine.
Separate 80-week trials have also reported retatrutide's sleep apnea results against placebo.
What this means for someone considering tirzepatide
The new result answers a question about Ozempic. It cannot rank retatrutide against tirzepatide, the molecule in Mounjaro and Zepbound. Our tirzepatide versus retatrutide comparison covers their broader differences.
Tirzepatide already has its own direct comparison with semaglutide. In SURPASS-2, published in the New England Journal of Medicine in 2021, researchers compared them for 40 weeks in adults with type 2 diabetes. That study used semaglutide 1 mg. Its results cannot be lined up against this new 2 mg comparison to calculate a winner between tirzepatide and retatrutide.
GLP-1 and GIP are gut-hormone signals involved in blood-sugar control. Semaglutide acts on GLP-1 and tirzepatide on both; retatrutide, Lilly says, also activates the receptor for glucagon, a third hormone involved in blood sugar. A prescriber considering tirzepatide weighs its own evidence alongside someone's history and current medicines.
What the result does not mean for semaglutide
The comparator matters. As of October 29, 2026, the day this article was written, the Ozempic prescribing information marked “Revised: 5/2026” lists 2 mg weekly as its maximum recommended dose. It was also not a test of semaglutide at weight-management doses: the Wegovy prescribing information, marked “Revised: 6/2026,” lists a 2.4 mg weekly maintenance dose and allows up to 7.2 mg weekly for some patients.
Dose differences have their own evidence. SUSTAIN FORTE, published in The Lancet Diabetes & Endocrinology in 2021, compared semaglutide 2 mg with 1 mg over 40 weeks. Blood-sugar reductions were greater with 2 mg in that trial. So a result against semaglutide depends on which dose was tested.
The new trial also enrolled people with diabetes. It cannot establish the same advantage in people without diabetes, or tell someone already taking semaglutide what switching would do.
The continued-treatment assumption matters too. A result assuming people stayed on medicine answers a different question from one that includes stopping it. Someone choosing treatment needs to understand both the possible benefit and how manageable the side effects are.
Side effects belong beside the weight figures
Dysesthesia means an unpleasant abnormal skin sensation, such as burning or tingling. Adverse events are health problems reported during a trial; a report does not by itself prove the medicine caused it.
Lilly's safety summary reported these event rates:
| Reported event | Retatrutide 9 mg | Retatrutide 12 mg | Ozempic 2 mg |
|---|---|---|---|
| Dysesthesia | 4.8% | 6.5% | 2.7% |
| Stopped because of adverse events | 4.8% | 7.9% | 2.7% |
Stomach and bowel symptoms were the most common events: diarrhea in 28.3% and 32.7% with retatrutide 9 mg and 12 mg versus 26.4% with Ozempic, nausea in 21.2% and 23.8% versus 21.3%, vomiting in 10.2% and 15.0% versus 13.2%, and constipation in 14.2% and 13.1% versus 19.8%. Lilly broadly describes most listed events as mild or moderate and usually resolving during treatment. It does not give dysesthesia-specific duration or stopping rates.
The retatrutide explainer covers the molecule's wider research history. This announcement adds a direct comparison, not a complete long-term safety record.
Retatrutide's status after the announcement
As of October 29, 2026, the day this article was written, retatrutide remains investigational, meaning still being tested, with no approved product anywhere, according to Lilly. It is not FDA-approved for any use.
FDA's GLP-1 page, marked “Content current as of: 10/01/2026,” states: “Retatrutide and cagrilintide cannot be used in compounding under federal law.” Trial results do not change that statement. Questions about outside sellers are covered in the counterfeit retatrutide report.
What a prescription conversation covers today
Semaglutide and tirzepatide have branded prescription medicines. Through Promise, they are dispensed by a licensed U.S. compounding pharmacy as compounded medications, meaning preparations made for individual prescriptions. These are different from FDA-approved products: the formulations offered here are not FDA-approved. A licensed provider may still prescribe — that decision is between you and your doctor.
At Promise, a licensed provider reviews every request, and not everyone qualifies. The discussion covers medical history, current medicines, treatment goals and side effects; the prescriber sets any actual dose.
What to watch next
The next useful detail is the full peer-reviewed report, which Lilly says will follow. That should make the methods and safety findings easier to examine than a topline announcement, the sponsor's initial summary.
As of October 29, 2026, the day this article was written, TRIUMPH-5's registry, last updated July 20, still lists the retatrutide-versus-tirzepatide trial as active, not recruiting, with no results posted. That separate trial addresses the comparison this announcement leaves open. Until its results arrive, the Ozempic finding cannot stand in for a tirzepatide result.
